Nasus Pharma Ltd. (NSRX)
Automate Your Wheel Strategy on NSRX
With Tiblio's Option Bot, you can configure your own wheel strategy including NSRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
BriefCast Publishes Transcript: Nasus Pharma NS002 Phase 2 Positive Topline Results Webinar Transcript
Published: March 19, 2026 by: GlobeNewsWire
Sentiment: Neutral
In a call hosted recently, Nasus Pharma (NYSE:NSRX) presented strong positive topline results from its Phase 2 clinical study evaluating NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis.
Read More
What's Going On With Nasus Pharma Stock On Wednesday
Published: March 18, 2026 by: Benzinga
Sentiment: Positive
The Phase 2 study results indicated that NS002 has the potential to exceed EpiPen performance, demonstrating statistically significant improvements in the time to therapeutic threshold.
Read More
Nasus Pharma CEO Issues 2025 Letter to Shareholders
Published: December 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
TEL AVIV, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma", “Nasus” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today issued a letter to its shareholders from its Chief Executive Officer, Dan Teleman.
Read More
Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against EpiPen
Read More
About Nasus Pharma Ltd. (NSRX)
- IPO Date 2025-08-13
- Website http://www.nasuspharma.com
- Industry Biotechnology
- CEO Dan Teleman
- Employees 2